小型猪动脉粥样硬化斑块稳定性模型研究

目前已有的动物模型在研究动脉粥样硬化斑块破裂、破裂的可控性及量化研究方面均不能满足研究的需要.为了建立类似于人类动脉粥样硬化病变的斑块模型,体外研究斑块稳定性,应用传统的高脂高胆固醇膳食诱导建立了小型猪动脉粥样硬化模型,并从血脂水平和斑块病理形态学特征方面加以了证实.该模型中斑块与人类成熟斑块的高度相似性使其成为研究斑块稳定性和斑块破裂的较好模型.从量化比较这一出发点着手,建立了一个体外可控可量化诱导斑块破裂模型,方法简单易行,是一个较好的量化研究斑块破裂和破裂相关因素间关系的实验模型.     

瑞舒伐他汀对载脂蛋白E 基因敲除小鼠动脉粥样硬化中 调节性T 细胞的影响

目的:探讨瑞舒伐他汀对载脂蛋白E基因敲除(ApoEKO)小鼠动脉粥样硬化中调节性T细胞的影响。方法:首先将30只ApoEKO小鼠建立动脉粥样硬化模型,随机分为高胆固醇饮食组(对照组)、瑞舒伐他汀低剂量组和瑞舒伐他汀高剂量组,各组分别给予蒸馏水或瑞舒伐他汀进行干预8周;将主动脉根部行冰冻切片油红染色,评估粥样硬化斑块面积大小;免疫组织化学法检测主动脉根部粥样硬化斑块处调节性T细胞(Treg)的表达。结果:各组小鼠均有动脉粥样硬化斑块形成,采用瑞舒伐他汀治疗的小鼠动脉粥样硬化斑块的面积明显小于未经治疗的小鼠(P<0.01),同时瑞舒伐他汀能明显增加粥样硬化病变处调节性T细胞的表达,且呈现剂效关系。结论:本实验观察到瑞舒伐他汀不仅能减小ApoEKO小鼠的主动脉粥样硬化斑块,且能使调节性T细胞的表达增多,推测瑞舒伐他汀可以通过促进调节性T细胞的生成而起到抑制动脉粥样硬化的作用。     

瑞舒伐他汀对载脂蛋白E基因敲除小鼠动脉粥样硬化中调节性T细胞的影响

目的：探讨瑞舒伐他汀对载脂蛋白E基因敲除（ApoEKO）小鼠动脉粥样硬化中调节性T细胞的影响。方法：首先将30只ApoEKO小鼠建立动脉粥样硬化模型,随机分为高胆固醇饮食组（对照组）、瑞舒伐他汀低剂量组和瑞舒伐他汀高剂量组,各组分别给予蒸馏水或瑞舒伐他汀进行干预8周;将主动脉根部行冰冻切片油红染色,评估粥样硬化斑块面积大小;免疫组织化学法检测主动脉根部粥样硬化斑块处调节性T细胞（Treg）的表达。结果：各组小鼠均有动脉粥样硬化斑块形成,采用瑞舒伐他汀治疗的小鼠动脉粥样硬化斑块的面积明显小于未经治疗的小鼠（P〈0.01）,同时瑞舒伐他汀能明显增加粥样硬化病变处调节性T细胞的表达,且呈现剂效关系。结论：本实验观察到瑞舒伐他汀不仅能减小ApoEKO小鼠的主动脉粥样硬化斑块,且能使调节性T细胞的表达增多,推测瑞舒伐他汀可以通过促进调节性T细胞的生成而起到抑制动脉粥样硬化的作用。     

动脉粥样硬化动物模型制作方法的介绍

动脉粥样硬化动物模型在病因学、病理学及预防方面的研究中起着非常重要的作用。近年来,运用兔子、小鼠、大鼠、鹌鹑等成功地建立了大量高脂饲料、单纯药物、高脂饲料加药物、基因敲除鼠及基因工程模型等诱导的动物模型。本文介绍了这几种动物模型的制作方法,以期为动脉粥样硬化的深入研究提供参考。     

S-炔丙基半胱氨酸延缓动脉粥样硬化进展并上调内皮细胞中内皮型一氧化氮合酶磷酸化（英文）

本研究旨在探究炔丙基半胱氨酸(S-propargyl-cysteine, SPRC)对延缓小鼠动脉粥样硬化进展的保护作用。用ApoE-/-小鼠通过右侧颈动脉串联双狭窄(tandem stenosis, TS)联合西方饮食构建动脉粥样硬化易损斑块小鼠模型，测定血管损伤面积、血脂和炎症水平来评估SPRC的抗动脉粥样硬化作用，组织病理学分析以评估斑块稳定性。为探究SPRC的保护机制，体外培养人脐静脉内皮细胞(human umbilical vein endothelial cells, HUVECs)并用氧化型低密度脂蛋白(oxidized low-density lipoprotein,ox-LDL)刺激，用细胞活力测定试剂盒测定细胞活力，用Western blot和RT-qPCR分别检测磷酸化内皮型一氧化氮合酶(endothelial nitric oxide synthase, eNOS)蛋白和mRNA表达。结果表明，每天80 mg/kg SPRC组小鼠主动脉弓和颈动脉病变面积显著减少，血浆胆固醇和低密度脂蛋白胆固醇水平显著降低，斑块中的胶原水平增加，且斑块中基质金属蛋白9(matri...     

基质金属蛋白酶在动脉粥样硬化易损斑块中的分子影像学研究

大量研究表明,依赖Ca2+、Zn2+等金属离子的基质金属蛋白酶在动脉粥样硬化斑块处的表达与斑块的稳定性密切相关,易损斑块处基质金属蛋白酶表达水平增高.单光子发射体层成像、近红外荧光成像、磁共振成像等分子影像学的方法,能够动态无创地检测动物模型动脉斑块或人颈动脉斑块切除后标本中基质金属蛋白酶的表达水平,不仅可以提示疾病的...     

基因修饰小鼠在脂代谢紊乱与动脉粥样硬化研究中的新进展

近十余年来,载脂蛋白(ApoE)与低密度脂蛋白(LDL)受体 (LDLr)基因敲除小鼠已成为研究脂代谢和动脉粥样硬化最为常用的模型.在这两种小鼠模型基础上,通过与不同的转基因、基因敲除小鼠杂交,产生了多种脂代谢紊乱和动脉粥样硬化小鼠模型,为发现调控血浆脂蛋白以及动脉粥样硬化发生的机制,创造了有利条件.此外,新的严重高甘油三酯血症小鼠模型也制备成功,本文笔者研究组研究了其中的脂蛋白脂酶缺陷模型与代谢性疾病的关系,得到了许多有意义的结果.而利用不同转基因和去基因小鼠作为供体, 以及ApoE或LDL受体缺陷小鼠作为接受体的骨髓移植技术,则大大丰富了人们对于巨噬细胞中不同基因在动脉粥样硬化发生、发展和消退过程中作用的认识.动脉粥样硬化的易损斑块形成是近年来的一个研究热点,应用小鼠模型进行模拟也取得了一定的成功.然而,小鼠与人类在脂代谢和动脉粥样硬化中存在很大的种系差异,本文对此也予以评述.     

不同程度内质网应激对ApoE-/- 小鼠动脉粥样硬化斑块稳定性的影响

目的:采用Apo E-/-小鼠建立不稳定动脉粥样硬化斑块模型,给予不同剂量衣霉素,观察其对动脉粥样硬化斑块稳定性的影响。方法:取40只6-8周的Apo E-/-小鼠随机分为对照组和手术组。对照组小鼠给予正常饮食;手术组小鼠行右侧颈总动脉套管术(Perivascular carotid collar placement,PCCP),同时给予高脂喂养。9周末分别取对照组和手术组小鼠颈动脉,HE染色观察小鼠颈动脉斑块形成情况。成功造模后,将小鼠随机分为正常对照组、单纯PCCP组、小剂量衣霉素组和大剂量衣霉素组;正常对照组和单纯PCCP组给予生理盐水腹腔注射,小剂量衣霉素组和大剂量衣霉素组分别给予小剂量衣霉素、大剂量衣霉素腹腔注射。2周后,处死小鼠,通过HE染色观察颈动脉斑块形态,油红O染色观察斑块内脂质聚集,抗巨噬细胞免疫组化染色观察斑块内巨噬细胞聚集,Western-blot检内质网应激标志蛋白GRP78和自噬标志蛋白Atg7、P62的表达水平。结果:HE染色结果显示:与单纯PCCP组和大剂量衣霉素组相比,小剂量衣霉素组颈动脉腔内的斑块脂质池减少,斑块结构较为完整且相对稳定;油红O染色结果显示:小剂量衣霉素组斑块内脂质含量显著降低(P0.05 vs单纯PCCP组和大剂量衣霉素组);巨噬细胞免疫组化染色显示:与单纯PCCP组和大剂量衣霉素组相比,小剂量衣霉素组斑块内巨噬细胞的含量显著降低(P0.05);Western-blot结果显示:小剂量衣霉素干预诱导的一定程度的内质网应激可以适度上调自噬(P0.05 vs单纯PCCP组和大剂量衣霉素组)。结论:PCCP手术加高脂饮食可以短期成功建立小鼠不稳定动脉粥样硬化斑块模型,其动脉粥样硬化斑块不稳定性较高,而小剂量衣霉素干预可以使得颈动脉管腔内斑块相对较小,内部脂质池明显较小,纤维帽变厚且结构更完整,斑块结构较稳定;斑块内脂质含量降低;巨噬细胞含量明显降低,且小剂量衣霉素组自噬水平适度上调。因此,小剂量衣霉素干预引起的适度的内质网应激一定程度对动脉粥样硬化斑块起到保护作用。     

葛根素延缓动脉粥样硬化进展的机制研究

目的:明确葛根素(Pur)对小鼠动脉粥样硬化斑块稳定性的治疗作用及其潜在机制。方法:用高脂饮食喂养成年小鼠诱导动脉粥样硬化模型,将小鼠分为Con组,ApoE~(-/-)组,ApoE~(-/-)+Pur组。采用HE染色分别检测各组小鼠中动脉粥样硬化斑块面积,免疫荧光染色检测斑块中MMP2的阳性区域面积。用50μg/mL ox-LDL干预巨噬细胞诱导动脉粥样硬化细胞模型,并用Ad-sh-Sirt3干扰Sirt3表达,将细胞分为Con组、ox-LDL组、ox-LDL+Pur组、ox-LDL+Pur+Ad-sh-Sirt3组。Western-blot检测Sirt3表达含量,TUNEL法检测巨噬细胞凋亡。结果:动物水平,与Con组相比,ApoE~(-/-)组小鼠出现了显著的动脉粥样硬化斑块,ApoE~(-/-)组小鼠MMP2阳性区域面积显著高于Con组(P0.05);Pur处理后,ApoE~(-/-)+Pur组动脉粥样硬化斑块面积明显低于ApoE~(-/-)组(P0.05),MMP2的阳性区域面积显著低于ApoE~(-/-)组(P0.05)。细胞水平,Western结果显示,与对照组相比,ox-LDL组Sirt3表达量显著降低(P0.05),ox-LDL+Pur组Sirt3表达水平显著高于ox-LDL组(P0.05)。相比于Con组,ox-LDL组巨噬细胞凋亡水平显著升高(P0.05);给予Pur处理后,相比于单纯ox-LDL组,ox-LDL+Pur组巨噬细胞的凋亡水平显著降低(P0.05)。Ad-sh-Sirt3处理消除了葛根素对于巨噬细胞凋亡的抑制作用(P0.05)。结论:外源性Pur可能通过激活Sirt3表达,进一步降低巨噬细胞凋亡水平,减少巨噬细胞的浸润,增加动脉粥样硬化斑块稳定性。     

三七总皂苷通过调节TLR4/SYK信号抑制ApoE 基因敲除小鼠动脉粥样硬化泡沫细胞的形成

三七总皂苷(Panax notoginseng saponins, PNS)是从五加科人参属植物三七根部提取的有效活性成分,临床广泛应用于动脉粥样硬化疾病的治疗,但其相关机制尚不完全清楚,本课题对ApoE基因敲除(ApoE~(-/-))小鼠的体内实验研究发现PNS具有明显的改善血脂的功能,并对小鼠动脉粥样硬化斑块的形成具有抑制作用,其分子机制与TLR4/SYK信号通路相关;进一步通过体外细胞实验发现PNS能够抑制小鼠斑块内巨噬细胞的吞噬能力和CD36的表达,从而抑制泡沫细胞的形成。因此我们认为三七总皂苷可通过调节TLR4/SYK信号抑制ApoE~(-/-)小鼠泡沫细胞的形成从而抑制动脉粥样硬化的进展。     

Early-onset Formation of Parenchymal Plaque Amyloid Abrogates Cerebral Microvascular Amyloid Accumulation in Transgenic Mice

The fibrillar assembly and deposition of amyloid β (Aβ) protein, a key pathology of Alzheimer disease, can occur in the form of parenchymal amyloid plaques and cerebral amyloid angiopathy (CAA). Familial forms of CAA exist in the absence of appreciable parenchymal amyloid pathology. The molecular interplay between parenchymal amyloid plaques and CAA is unclear. Here we investigated how early-onset parenchymal amyloid plaques impact the development of microvascular amyloid in transgenic mice. Tg-5xFAD mice, which produce non-mutated human Aβ and develop early-onset parenchymal amyloid plaques, were bred to Tg-SwDI mice, which produce familial CAA mutant human Aβ and develop cerebral microvascular amyloid. The bigenic mice presented with an elevated accumulation of Aβ and fibrillar amyloid in the brain compared with either single transgenic line. Tg-SwDI/Tg-5xFAD mice were devoid of microvascular amyloid, the prominent pathology of Tg-SwDI mice, but exhibited larger parenchymal amyloid plaques compared with Tg-5xFAD mice. The larger parenchymal amyloid deposits were associated with a higher loss of cortical neurons and elevated activated microglia in the bigenic Tg-SwDI/Tg-5xFAD mice. The periphery of parenchymal amyloid plaques was largely composed of CAA mutant Aβ. Non-mutated Aβ fibril seeds promoted CAA mutant Aβ fibril formation in vitro. Further, intrahippocampal administration of biotin-labeled CAA mutant Aβ peptide accumulated on and adjacent to pre-existing parenchymal amyloid plaques in Tg-5xFAD mice. These findings indicate that early-onset parenchymal amyloid plaques can serve as a scaffold to capture CAA mutant Aβ peptides and prevent their accumulation in cerebral microvessels.     

Existence of different types of senile plaques between brain and spinal cord of TgCRND8 mice

Conflicting findings exist regarding the formation of diffuse and dense-core β-amyloid (Aβ) plaques in Alzheimer’s disease (AD). In the present study, we characterized Aβ plaque types in the brain and spinal cord of TgCRND8 mice, which express a transgene incorporating both the Indiana mutation (V717F) and the Swedish mutations (K670N/M671L) in the human amyloid-β protein precursor (APP) gene. By combining immunohistochemistry and thioflavin S staining, we were able to define dense-core and diffuse plaques in neocortex of the brain and spinal cord of 9 week-, 5 month-, 10 month- and 20-month-old TgCRND8 mice. The senile plaques in the neocortex were predominantly dense-core plaques, even in the youngest mice. However, diffuse plaques were instead detected in spinal cord of the mice, regardless of age. Our results that relative predominance of dense-core plaques in the neocortex and diffuse plaques in the spinal cord of TgCNRD8 mice of all disease durations argue against the notion that diffuse plaques may represent an early stage in the evolution of dense-core plaques. Furthermore, we also found that the ratio of Aβ42/Aβ40 of the brain was much higher than that of the spinal cord by Aβ ELISA assay. Our findings strongly indicate that diffuse and dense-core plaques may form via independent processes in AD and Aβ42 is more prone to form dense-core plaques than is Aβ40.     

Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks

Alzheimer's disease is characterized by the deposition of senile plaques and progressive dementia. The molecular mechanisms that couple plaque deposition to neural system failure, however, are unknown. Using transgenic mouse models of AD together with multiphoton imaging, we measured neuronal calcium in individual neurites and spines in vivo using the genetically encoded calcium indicator Yellow Cameleon 3.6. Quantitative imaging revealed elevated [Ca(2+)]i (calcium overload) in approximately 20% of neurites in APP mice with cortical plaques, compared to less than 5% in wild-type mice, PS1 mutant mice, or young APP mice (animals without cortical plaques). Calcium overload depended on the existence and proximity to plaques. The downstream consequences included the loss of spinodendritic calcium compartmentalization (critical for synaptic integration) and a distortion of neuritic morphologies mediated, in part, by the phosphatase calcineurin. Together, these data demonstrate that senile plaques impair neuritic calcium homeostasis in vivo and result in the structural and functional disruption of neuronal networks.     

Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation

The γ-secretase complex is a major therapeutic target for the prevention and treatment of Alzheimer's disease. Previous studies have shown that treatment of young APP mice with specific inhibitors of γ-secretase prevented formation of new plaques. It has not yet been shown directly whether existing plaques would be affected by γ-secretase inhibitor treatment. Similarly, alterations in neuronal morphology in the immediate vicinity of plaques represent a plaque-specific neurotoxic effect. Reversal of these alterations is an important endpoint of successful therapy whether or not a treatment affects plaque size. In the present study we used longitudinal imaging in vivo with multiphoton microscopy to study the effects of the orally active γ-secretase inhibitor LY-411575 in 10–11 month old APP:PS1 mice with established amyloid pathology and neuritic abnormalities. Neurons expressed YFP allowing fluorescent detection of morphology whereas plaques were labelled with methoxy-XO4. The same identified neurites and plaques were followed in weekly imaging sessions in living mice treated daily (5 mg/kg) for 3 weeks with the compound. Although LY-411575 reduced Aβ levels in plasma and brain, it did not have an effect on the size of existing plaques. There was also no effect on the abnormal neuritic curvature near plaques, or the dystrophies in very close proximity to senile plaques. Our results suggest that therapeutics aimed at inhibition of Aβ generation are less effective for reversal of existing plaques than for prevention of new plaque formation and have no effect on the plaque-mediated neuritic abnormalities, at least under these conditions where Aβ production is suppressed but not completely blocked. Therefore, a combination therapy of Aβ suppression with agents that increase clearance of amyloid and/or prevent neurotoxicity might be needed for a more effective treatment in patients with pre-existing pathology.     

Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology

Increased expression and altered processing of the amyloid precursor protein (APP) and generation of beta-amyloid peptides is important in the pathogenesis of amyloid plaques in Alzheimer's disease (AD). Transgenic Tg2576 mice overexpressing the Swedish mutation of human APP exhibit beta-amyloid deposition in the neocortex and limbic areas, accompanied by gliosis and dystrophic neurites. However, murine plaques appear to be less cross-linked and the mice show a lower degree of inflammation and neurodegeneration than AD patients. 'Advanced glycation endproducts (AGEs)', formed by reaction of proteins with reactive sugars or dicarbonyl compounds, are able to cross-link proteins and to activate glial cells, and are thus contributing to plaque stability and plaque-induced inflammation in AD. In this study, we analyze the tissue distribution of AGEs and the pro-inflammatory cytokines IL-1beta and TNF-alpha in 24-month-old Tg2576 mice, and compare the AGE distribution in these mice with a younger age group (13 months old) and a typical Alzheimer's disease patient. Around 70% of the amyloid plaque cores in the 24-month-old mice are devoid of AGEs, which might explain their solubility in physiological buffers. Plaque associated glia, which express IL-1beta and TNF-alpha, contain a significant amount of AGEs, suggesting that plaques, i.e. Abeta as its major component, can induce intracellular AGE formation and the expression of the cytokines on its own. In the 13-month-old transgenic mice, AGEs staining can neither be detected in plaques nor in glial cells. In contrast, AGEs are present in high amounts in both plaques and glia in the human AD patient. The data obtained in this show interesting differences between the transgenic mouse model and AD patients, which should be considered using the transgenic approach to test therapeutical strategies to eliminate plaques or to attenuate the inflammatory response in AD.     

Interaction of human and mouse Abeta peptides

Transgenic mice over-expressing mutant human amyloid precursor protein have become an important tool for research on Alzheimer's disease (AD) and, in particular, for therapeutic screening. Many models have reported formation of amyloid plaques with age as is detected in AD. However, the plaques generated in transgenic mice are more soluble than human plaques. Differences in solubility may occur for a number of reasons; one proposal is the presence of murine Abeta peptides within the CNS milieu. Here, we report the interaction of human and murine Abeta peptides, Abeta40 and Abeta42, utilizing a fluorescence assay to monitor formation of mixed pre-fibrillar aggregates, electron microscopy to examine morphological characteristics and detergent solubility to monitor stability. Our results demonstrate that interspecies Abeta aggregates and fibres are readily formed and are more stable than homogenous human fibres. Furthermore, these results suggest that the presence of endogenous murine Abeta in human APP transgenic mice does not account for the increased solubility of plaques.     

Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits

Previous studies have shown that inducing autophagy ameliorates early cognitive deficits associated with the build-up of soluble amyloid-β (Aβ). However, the effects of inducing autophagy on plaques and tangles are yet to be determined. While soluble Aβ and tau represent toxic species in Alzheimer's disease (AD) pathogenesis, there is well documented evidence that plaques and tangles also are detrimental to normal brain function. Thus, it is critical to assess the effects of inducing autophagy in an animal model with established plaques and tangles. Here we show that rapamycin, when given prophylactically to 2-month-old 3xTg-AD mice throughout their life, induces autophagy and significantly reduces plaques, tangles and cognitive deficits. In contrast, inducing autophagy in 15-month-old 3xTg-AD mice, which have established plaques and tangles, has no effects on AD-like pathology and cognitive deficits. In conclusion, we show that autophagy induction via rapamycin may represent a valid therapeutic strategy in AD when administered early in the disease progression.     

Electron microscopic and confocal laser microscopy analysis of amyloid plaques in chronic wasting disease transmitted to transgenic mice

We report here on the ultrastructure of amyloid plaques in chronic wasting disease (CWD) transmitted to Tg20 transgenic mice overexpressing prion protein (PrP^c). We identified three main types of amyloid deposits in mCWD: large amyloid deposits, unicentric plaques similar to kuru plaques in human prion diseases and multicentric plaques reminiscent of plaques typical of GSS. The most unique type of plaques were large subpial amyloid deposits. They were composed of large areas of amyloid fibrils but did not form ?star-like” appearances of unicentric plaques. All types of plaques were totally devoid of dystrophic neuritic elements. However, numerous microglial cells invaded them. The plaques observed by confocal laser microscope were of the same types as those analyzed by electron microscopy. Neuronal processes surrounding the plaques did not show typical features of neuroaxonal dystrophy.     

Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice

Both active and passive immunization to eliminate amyloid plaques from the brain of patients with Alzheimer's disease (AD) have confirmed that amyloid beta (Abeta) vaccination does not only result in clearance of Abeta plaques but improves behavioral-cognitive deficits in animal models of AD. In the present study, the levels of naturally occurring serum antibodies against Abeta were measured in Tg2576 mice at various ages using ELISA to determine the relationship between aging and the level of anti-Abeta autoantibody. The level of anti-Abeta antibody fell significantly at the age of 9 months, at the age when amyloid plaques started to appear in the brain of Tg2576 mice, and was persistently low thereafter. However, serum immunoglobulin (Ig) level was elevated in older transgenic mice compared with younger transgenic mice suggesting that the reduced level of anti-Abeta autoantibody was not merely due to deterioration of the immune response in aged Tg2576 mice.     

Autophagy links inflammasomes to atherosclerotic progression

We investigated the role of autophagy in atherosclerosis. During plaque formation in mice, autophagic markers colocalized predominantly with macrophages (mφ). Atherosclerotic aortas had elevated levels of p62, suggesting that dysfunctional autophagy is characteristic of plaques. To determine whether autophagy directly influences atherogenesis, we characterized Beclin-1 heterozygous-null and mφ-specific ATG5-null (ATG5-mφKO) mice, commonly used models of autophagy haploinsufficiency and deficiency, respectively. Haploinsufficent Beclin-1 mice had no atherosclerotic phenotype, but ATG5-mφKO mice had increased plaques, suggesting an essential role for basal levels of autophagy in atheroprotection. Defective autophagy is associated with proatherogenic inflammasome activation. Classic inflammasome markers were robustly induced in ATG5-null mφ, especially when coincubated with cholesterol crystals. Moreover, cholesterol crystals appear to be increased in ATG5-mφKO plaques, suggesting a potentially vicious cycle of crystal formation and inflammasome activation in autophagy-deficient plaques. These results show that autophagy becomes dysfunctional in atherosclerosis and its deficiency promotes atherosclerosis in part through inflammasome hyperactivation.